@article{ca60dd6945cc4966b20ea5ea7aa333a0,
title = "Can a biomarker triage test reduce colonoscopy burden in fecal immunochemical test screening?",
abstract = "Aim: To assess the potential of biomarker triage testing (BM-TT) in the Dutch colorectal cancer (CRC) screening program. Materials & methods: Using the Adenoma and Serrated pathway to Colorectal CAncer model, we simulated fecal immunochemical test (FIT)(47)-screening and various FIT plus BM-TT screening scenarios in which only individuals with both a positive FIT and BM-TT are referred to colonoscopy. Results: Adding a low polyp sensitivity BM-TT to FIT-screening reduced colonoscopy burden (89-100%) while increasing CRC mortality (27-41%) compared with FIT47-screening only. The FIT plus high polyp sensitivity BM-TT scenarios also decreased colonoscopy burden (71-89%) while hardly affecting CRC mortality (FIT47 0-4% increase, FIT15 2-7% decrease). Conclusion: Adding a BM-TT to FIT-screening considerably reduces colonoscopy burden, but could also decrease screening effectiveness. Combining FIT15 with a high polyp sensitivity BM-TT seems most promising.",
keywords = "biomarker test, colorectal cancer screening, screening burden, triage testing, COLORECTAL-CANCER, COST-EFFECTIVENESS, SERRATED PATHWAY, CT COLONOGRAPHY, IMPACT",
author = "Greuter, {Marjolein J. E.} and Beatriz Carvalho and {de Wit}, Meike and Evelien Dekker and Spaander, {Manon C. W.} and Meijer, {Gerrit A.} and {van Engeland}, Manon and Coupe, {Veerle M. H.}",
note = "Funding Information: Financial support for this study was provided by a SU2C-DCS International Translational Cancer Research Dream Team Grant (SU2C-AACR-DT1415, MEDOCC). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. B Carvalho, M de Wit, VMH Coup{\'e} and GA Meijer have several patents pending. GA Meijer also reports grants from AACR during the conduct of the study, nonfinancial support from Exact Sciences, nonfinancial support from Sysmex, other from Royal Philips, other from GlaxoSmithKline, other from Keosys SARL, other from Open Clinica LLC, other from Roche Diagnostics Nederland BV, other from The Hyve BV, other from Open Text, other from SURFSara BV, other from Vancis BV, other from CSC Computer Sciences BV and nonfinancial support from Sentinel CH SpA outside the submitted work. E Dekker has endoscopic equipment on loan of FujiFilm and receives a research grant from FujiFilm. She has received an honorarium for consultancy from FujiFilm, Tillots and Olympus and a speakers{\textquoteright} fee from Olympus and Roche. Besides, she is in the supervisory board of eNose. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2020",
year = "2020",
month = jun,
doi = "10.2217/cer-2019-0130",
language = "English",
volume = "9",
pages = "563--571",
journal = "Journal of Comparative Effectiveness Research",
issn = "2042-6305",
publisher = "Future Medicine Ltd.",
number = "8",
}